---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043052"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-09-17T12:30:40+00:00"
generated_at: "2026-09-17T12:35:17.768145+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies wins Hong Kong patent for CyPath Lung lung cancer diagnostic

## Summary
- Hong Kong IP Department granted Patent No. HK40048460 covering flow cytometry and fluorescent markers in sputum for lung cancer prediction.
- Patent complements 2025 China patent; strengthens IP in Asia, which accounts for ~1.6M new lung cancer cases annually.
- CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.
- Company holds patents/pending in US, Australia, Canada, China, EU, Japan, Mexico, Singapore.

## SEC filing metadata
- accession: 0001493152-26-043052
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-09-17T12:30:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/0001493152-26-043052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043052
- JSON: https://secwatch.observer/filing/0001493152-26-043052.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.